Intraoperative Tranexamic Acid in Radical Cystectomy: Impact on Bleeding, Thromboembolism, and Survival Outcomes
Perioperative blood transfusion has been reported in > 50% of patients undergoing Radical cystectomy (RC). Unfortunately, perioperative blood transfusion in patients undergoing RC has been associated with poor oncological outcomes. Tranexamic acid (TXA) use has been proposed to decrease the need for perioperative blood transfusion. Here, we seek to investigate the impact of intraoperative TXA on the risk of perioperative bleeding and VTE in patients undergoing radical cystectomy (RC). We also investigate its long-term impact on overall survival (OS) and cancer-specific survival outcomes (CSS).
Spontaneous resolution of primary obstructive megaureter: Risk stratification and prediction based on early sonographic factors
To describe and develop predictors for spontaneous resolution of primary obstructive megaureter (POM) from early ultrasound measures.
Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel
To evaluate long-term outcomes of primary chemoablation using a mitomycin reverse thermal gel (UGN-101) in patients with low-grade upper tract urothelial carcinoma.
Validation of Prognostic Models for Renal Cell Carcinoma Recurrence, Cancer Specific Mortality and All-Cause Mortality
Post-operative prognostic tools allow for improved prediction of future recurrence risk, patient counselling, assessment of eligibility for adjuvant treatments, and ensure appropriate follow-up surveillance. The purpose of this analysis is to validate existing prognostic models for patients with kidney cancer.
Reply: Development of a Novel Prediction Tool for Response to First-Line Treatments of Monosymptomatic Nocturnal Enuresis: A Randomized, Controlled, International, Multicenter Study (DRYCHILD)
Clinical and Demographic Factors Linked to Low-Value Emergency Department Visits in Pediatric Patients With Spina Bifida
Identifying factors associated with emergency visits that could be delivered at lower cost sites may help guide population health strategies for pediatric patients with spina bifida.
Cuff Conundrums: Best Practice Recommendations for Urethral Instrumentation With an Artificial Urinary Sphincter in Place
High 11-Ketotestosterone Linked to Shorter Time to Castration Resistance in Recurrent Nonmetastatic Prostate Cancer
The contribution of 11-oxygenated androgens to the progression of lethal prostate cancer (PCa) remains unresolved. We hypothesized that evaluating circulating levels of 11-oxygenated androgens, such as the androgen receptor agonist 11-ketotestosterone (11KT), could serve as a potential predictor of the onset of castration-resistant PCa (CRPC).
Letter: Development of a Novel Prediction Tool for Response to First-Line Treatments of Monosymptomatic Nocturnal Enuresis: A Randomized, Controlled, International, Multicenter Study (DRYCHILD)
Reply: Health Vulnerabilities of Spina Bifida Patients: Transition From Adolescents to Adults
Letter: Health Vulnerabilities of Spina Bifida Patients: Transition From Adolescents to Adults
Urologic Oncology: Bladder, Penis, and Urethral Cancer and Basic Principles of Oncology
Letter: Radiating for Two: Quantifying Radiation Exposure to Pregnant Urologists During Percutaneous Nephrolithotomy
Two-year efficacy and safety outcomes of the pivotal OASIS Study using the Revi System for treatment of urgency urinary incontinence
The BlueWind Medical Device, Revi, is a novel implantable tibial neuromodulation system powered by an external, battery-operated wearable that facilitates individually tailored stimulation to provide treatment for urgency urinary incontinence (i.e., overactive bladder wet). The Revi System is the first FDA-cleared implantable neuromodulation device which can be used without prior failure with more conservative treatment options. Two-year follow-up results of the OASIS Study are presented.
Reply: Development of a Novel Prediction Tool for Response to First-Line Treatments of Monosymptomatic Nocturnal Enuresis: A Randomized, Controlled, International, Multicenter Study (DRYCHILD)
Uromonitor: Clinical Validation and Performance Assessment of a Urinary Biomarker Within the Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer
Alternative, noninvasive, cost-effective methods to complement or serve as substitutes to current standard-of-care (SOC) procedures in NMIBC follow-up are needed. Uromonitor is a urine biomarker test detecting bladder cancer recurrence through the screening of , , and hotspot mutations. The aim of this study was to assess Uromonitor performance by comparing it with the current SOC methods.
Urologic Oncology: Bladder, Penis, and Urethral Cancer, and Basic Principles of Oncology
